Graves' Disease

Disease

Related News

argenx Reports $1.3B Q1 2026 Revenue, PDUFA Date Set for May 10 in Seronegative gMG

May 07, 2026

argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.

Endometriosis Linked to Higher Risk of Thyroid Disorders; ACOG Issues New Diagnostic Guidance

Mar 03, 2026

Women with endometriosis face increased long-term risk for thyroid disorders including hypothyroidism and Graves disease, according to a 20-year retrospective study. ACOG released new clinical guidance aimed at reducing diagnostic delays through clinical diagnosis and earlier treatment initiation.